Deletion mapping of chromosome 19 in human gliomas

Deimling, Andreas von; Nagel, Judith; Bender, Bernhard U.; Lenartz, Doris; Schramm, Johannes; Louis, David N.; Wiestler, Otmar D.

doi:10.1002/ijc.2910570511

Cited by 85 publications

(38 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple investigations have progressively narrowed the 19q common deletion region to an interval within the 19q13.3 cytogenetic band (120,(122)(123)(124), and several positional and/or functional candidates for the 19q tumor suppressor gene have been eliminated based on mutational analyses (125)(126)(127)(128)(129)(130). The 19q glioma tumor suppressor gene, however, remains to be identified.…”

Section: Chromosome Arm 19qmentioning

confidence: 99%

“…Deletion mapping of 19q in oligodendrogliomas is complicated by the rare occurrence of tumors with only partial deletion of 19q. Thus, hypothesizing that astrocytic and oligodendroglial tumors share at least one 19q tumor suppressor gene in common, deletion mapping studies of the oligodendroglioma 19q gene have primarily relied upon astrocytoma samples (120,(122)(123)(124).…”

Section: Chromosome Arm 1p and 19qmentioning

confidence: 99%

See 1 more Smart Citation

Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications

Smith

Jenkins²

2000

Front Biosci

146

View full text Add to dashboard Cite

Our understanding of diffuse glioma development and progression has expanded remarkably over the past decade. As the genetic alterations responsible for these tumors are identified, molecular models of glioma pathogenesis are emerging and hold great promise to explain the biologic mechanisms of these neoplasms. Although these models continue to evolve and remain highly simplified, some of the genetic alterations that they encompass appear to be prognostically useful. Among the astrocytic gliomas, age and tumor grade are the most powerful indicators of patient survival, however, a wide range of variability remains, particularly among the lowgrade and anaplastic astrocytomas. Recent reports indicate that alterations of the PTEN tumor suppressor gene are independent predictors of overall survival for anaplastic astrocytoma patients, helping to distinguish the cases with behavior resembling their more malignant counterparts, the glioblastomas.Among the oligodendroglial tumors, alterations of the 1p and 19q chromosome arms have emerged as potentially powerful predictors of overall patient survival and in vivo chemotherapeutic response, while alterations of the p16/CDKN2A tumor suppressor gene suggest shorter overall survival. As our molecular models continue to improve, through functional analyses and the identification of additional genetic contributors, we will expand our capacity to more effectively prognose these patients and to design rational therapeutic strategies. INTRODUCTIONDiffuse gliomas exhibit an inherent tendency to progress to more malignant phenotypes and a broad range of clinical behavior. Classification of diffuse gliomas by histologic subtype (figure 1) and malignancy grade (figure 2),

show abstract

Section: Chromosome Arm 19qmentioning

confidence: 99%

Section: Chromosome Arm 1p and 19qmentioning

confidence: 99%

Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications

Smith

Jenkins²

2000

Front Biosci

146

View full text Add to dashboard Cite

show abstract

“…Comprehensive genomic characterization by integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in >200 glioblastomas has then refined the definition of human glioblastoma genes and core pathways (The Cancer Genome Atlas [TGCA] Research Network, 2008). Deletion of chromosome 19q is nevertheless of particular interest, as it is shared by all three glioma subtypes, occurring in approximately 75% of oligodendrogliomas, 45% of mixed oligoastrocytomas and 40% of astrocytomas (von Deimling et al, 1992(von Deimling et al, , 1994, where it is associated with the transition from low-grade to anaplastic tumours (Ohgaki et al, 1995;Ritland et al, 1995;Smith et al, 1999) (Box 2).…”

Section: Non-random Chromosomal Aberrations In Gliomas: the 19q13 Abnmentioning

confidence: 99%

Role of the Centrosomal MARK4 Protein in Gliomagenesis

Magnani¹,

Novielli²,

Larizza³

2011

Glioma - Exploring Its Biology and Practical Relevance

View full text Add to dashboard Cite

“…Further studies have shown that oligodendroglial tumors display a distinctive genetic pro le that consists of loss of the entire 1p and 19q chromosomal arms with retention of 1q and 19p (Kraus et al, 1995;Ritland et al, 1995). Although the smallest region of overlapping deletion on 19q has been narrowed to a 900-kb region (Rosenberg et al, 1996;Yong et al, 1995), the small deletions have generally been in astrocytic lesions, not oligodendroglial ones (Ritland et al, 1995;von Deimling et al, 1994). The incidence of 19q loss for oligodendroglial tumors is as high as 81% in some studies (Reifenberger et al, 1994), while LOH for 1p has been reported in up to 94% of these tumors (Bello et al, 1995).…”

Section: Reports By Ransom Et Al (1991) and Von Deimling Et Al (199mentioning

confidence: 99%

Morphologic and molecular genetic aspects of oligodendroglial neoplasms

Bigner¹

1999

Neuro-Oncology

View full text Add to dashboard Cite

Morphologic criteria for diagnosing oligodendrogliomas and for classifying them as well-differentiated (World Health Organization grade II) and anaplastic (World Health Organization grade III) are well recognized. Nevertheless, applying these guidelines to speci c cases often reveals discrepancies among different observers. In addition, whether a given tumor also contains an astrocytic component may be debatable. Loss of heterozygosity studies have demonstrated that oligodendroglial neoplasms have a high incidence of loss of the 1p and 19q chromosomal arms. Although loss of heterozygosity for portions of 19q are sometimes seen in astrocytic neoplasms, these tumors seldom show complete loss of 19q accompanied by loss of 1p. Loss of 9p or homozygous deletion of the CDKN2 gene or both are associated with anaplastic oligodendrogliomas, whereas loss of 17p or TP53 gene mutations or both are frequent in astrocytomas, but rare in oligodendrogliomas. These observations suggest that molecular genetic parameters could provide an objective, reproducible framework for classifying oligodendroglial neoplasms. Neuro-Oncology 1, 52-60, 1999 (Posted to Neuro-Oncology [serial online], Doc. 98-20, January 19, 1999 O ligodendrogliomas were rst described as a speci c histologic type of glial neoplasm by Bailey and colleagues (Bailey and Bucy, 1929;Bailey and Cushing, 1926). Since the original description, these tumors have been recognized as often containing a mixture of astrocytic and oligodendroglial elements. In addition, anaplastic oligodendrogliomas, which display histologic features such as cellular atypia, increased cellular density, endothelial proliferation, and necrosis, often behave more aggressively than the slowgrowing, well-differentiated tumors. The WHO 3 classication scheme for brain tumors sets forth criteria for distinguishing between grades II and III oligodendrogliomas and mixed gliomas. Nevertheless, application of these criteria to individual cases often reveals a lack of consistency and reproducibility in classifying oligodendroglial tumors among observers.Objective means of determining whether a tumor contains neoplastic oligodendroglial or astrocytic elements or both and distinguishing between grades II and III lesions are critical because the survival and therapy is different for each category of tumor. A subset of oligodendroglial tumors characterized by loss of chromosomal arms 1p and 19q suggests that demonstration of this pattern by LOH, FISH, or CGH studies might provide an objective, reproducible means of identifying this category of tumors. Furthermore, LOH for 9p or deletions of the CDKN2 gene or both appear to occur more frequently in anaplastic oligodendrogliomas than in well-differentiated, grade II tumors. Maintz et al. (1997) observed that though oligodendroglial tumors have frequent loss of 1p and 19q and a low incidence of TP53 gene mutations, astrocytomas have the opposite pro le. They evaluated these parameters in a series of gliomas, which included 38 oligoastrocytomas of grades II and ...

show abstract

Deletion mapping of chromosome 19 in human gliomas

Cited by 85 publications

References 15 publications

Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications

Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications

Role of the Centrosomal MARK4 Protein in Gliomagenesis

Morphologic and molecular genetic aspects of oligodendroglial neoplasms

Contact Info

Product

Resources

About